Carried by: CIGAL Intergroup (French cooperative groups for adult haematological malignancies: ALFA, FILO and GRAALL), Haematological Oncomolpath Group (APHP Molecular Tumour Genetics Platform), French Group of Molecular Biologists specialising in Malignant Haematological Diseases (GBMHM)
References:
Clinician(s): Raphaël ITZYKSON
Biologist(s): Emmanuelle CLAPPIER
Presentation
Acute leukaemias (ALL and AML) are aggressive cancers with a very poor prognosis if first-line treatment fails, particularly in adults. STHD of these chemoresistant tumours will enable comprehensive characterisation, in a single step, of genomic alterations in tumour cells and identification of potential molecular targets (theranostic markers) or deregulated biological pathways that are accessible to targeted therapies.
Criteria before considering a discussion in MDM-FMG
- Acute myeloid or lymphoblastic leukaemia in relapse or refractory
and
- Tumour material available: blood or bone marrow with sufficient infiltration (or sorted tumour cells)
and
- Non-tumoral material available: blood or bone marrow at remission (verified), or skin biopsy possible in the absence of remission
and
- Patient eligible for active treatment
MDM cartography
MDM
Type of the MDM
City of the coordinator
Name, first name, and email of the contact
MDM-FMG National Adult Oncology and Haematology
National
Paris, Grenoble, St Etienne
Emmanuelle CLAPPIER
Raphaël ITZYKSON
Pascale FLANDRIN-GRESTA
pascale.flandrin-gresta@chu-st-etienne.fr
Sophie PARK